Literature DB >> 9580617

Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation.

M B Burton1, G F Gebhart.   

Abstract

The objective of this study was to evaluate the effects of kappa-opioid receptor agonists on pressor and visceromotor responses to colorectal distension in awake, unrestrained rats, a model of visceral pain. Because visceral pain can be enhanced in the presence of inflammation, the study was conducted in rats that had been given either intracolonic saline or 5% acetic acid 6 hr before drug administration. We developed a method of staircase colorectal distension as a means of obtaining stimulus-response functions over a short period of time. Kappa-opioid receptor agonists, given i.v. in a cumulative dose paradigm, dose-dependently attenuated both the pressor and visceromotor responses to colorectal distension. In addition, all drugs tested also increased response threshold. The rank order of potency of the drugs tested was: CI977 > U69,593 > U50,488 > or = morphine > or = EMD61,753 > ICI204,448. Effective doses of these drugs were antagonized by naloxone, but not by either of two kappa-opioid receptor-selective antagonists (nor-binaltorphimine and 2-(3,4-dichlorophenyl)-N-methyl-N-(1-[3-isothiocyanate phenyl]-2-[1-pyrrolidinyl]ethyl)-acetamide). Acute inflammation of the colon did not lead to changes in the potency of the agonists tested. The present results provide further evidence that kappa-opioid receptor agonists significantly attenuate visceral nociception and, in conjunction with other information, suggest that a peripherally restricted kappa-opioid receptor agonist would be therapeutically effective in relieving visceral pain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580617

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

2.  Opioid-induced bowel dysfunction.

Authors:  Howard Y Chang; Anthony J Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

3.  A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.

Authors:  Anne E Olesen; Richard Upton; David J R Foster; Camilla Staahl; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

4.  A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.

Authors:  Anne E Olesen; Kim Kristensen; Camilla Staahl; Sherron Kell; Gilbert Y Wong; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

5.  Effects of peripheral κ opioid receptor activation on inflammatory mechanical hyperalgesia in male and female rats.

Authors:  Q-Schick Auh; Jin Y Ro
Journal:  Neurosci Lett       Date:  2012-07-20       Impact factor: 3.046

6.  Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse.

Authors:  Monica Verma-Gandhu; Elena F Verdu; Premysl Bercik; Patricia A Blennerhassett; Nafia Al-Mutawaly; Jean-Eric Ghia; Stephen M Collins
Journal:  Gut       Date:  2006-10-03       Impact factor: 23.059

7.  Effects of octreotide on responses to colorectal distension in the rat.

Authors:  X Su; M B Burton; G F Gebhart
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

8.  kappa -opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action.

Authors:  S K Joshi; X Su; F Porreca; G F Gebhart
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

9.  Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats.

Authors:  Nahid Fakhraei; Nina Javadian; Reza Rahimian; Fatemeh Nili; Nastaran Rahimi; Shiva Hashemizadeh; Ahmad Reza Dehpour
Journal:  Inflammopharmacology       Date:  2018-10-15       Impact factor: 4.473

Review 10.  Pharmacotherapy: non-serotonergic mechanisms.

Authors:  R Spiller
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.